| Autor: |
Abushanab, Dina, AL-Marridi, Wafa, Al Hail, Moza, Abdul Rouf, Palli Valappila, ElKassem, Wessam, Thomas, Binny, Alsoub, Hussam, Ademi, Zanfina, Hanssens, Yolande, Enany, Rasha El, Al-Badriyeh, Daoud |
| Zdroj: |
Journal of Pharmaceutical Policy & Practice; Dec2024, Vol. 17 Issue 1, p1-27, 27p |
| Abstrakt: |
Objective: To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar. Methods: Patient records were retrospectively reviewed during two periods: preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP. Results: A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development. Conclusions: Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$−1,317) per 100-patient beds, which exceeded the cost savings achieved. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
